


Dulaglutide, glargine plus lispro improve glycemic control

June 20 2016



(HealthDay)—Dulaglutide and glargine in combination with prandial

lispro are associated with a similar percentage of time spent in the normoglycemic range, according to a study published online June 9 in *Diabetes, Obesity and Metabolism*.

Johan Jendle, M.D., Ph.D., from Örebro University in Sweden, and colleagues randomized 884 conventional insulin regimen-treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg, and glargine, in combination with prandial insulin lispro. In a continuous [glucose](#) monitoring (CGM) substudy, 144 patients were inserted with a Medtronic CGMS iPro CGM device to enable three-day glucose monitoring.

The researchers found that mean CGM glucose decreased in all treatment groups (dulaglutide 1.5 mg and 0.75 mg, and glargine) at week 26; the differences between groups were not statistically significant. The percentage time in 3.9 to 7.8 mmol/L range was similar for all treatment groups. The percentage time in 3.9 to 10.0 mmol/L range was greater for dulaglutide 1.5 mg versus glargine (P

"In combination with prandial lispro, [treatment](#) with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycemic range, but dulaglutide provided an improved balance between the proportion of values within the near-normoglycemia range and values within the hypoglycemic range," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly, which manufactures dulaglutide and funded the study.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Dulaglutide, glargine plus lispro improve glyceimic control (2016, June 20) retrieved 18 January 2023 from <https://medicalxpress.com/news/2016-06-dulaglutide-glargine-lispro-glyceimic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.